Debiopharm

Presented at ECCMID 2016, Amsterdam, NL Frédéric Peyrusson (1), Françoise Van Bambeke (1), Guennaëlle Dieppois (2), Frederick Wittke (2), Paul M. Tulkens

AAPS Baltimore, Nov 7-11, 2004 N. Ubrich, P. Maincent, F. El Ghazouani, E. Emond, C. Vigneron, E. Vuaridel, A. Carrio, S. Bernard, J.M. Dumont, B. Ducrey

Simona Ispas-Jouron1, Annick Menetrey1, Dalit Rechavi-Robinson1, Daniel Biasse1, Moritz Marquardt1, Bruno Gavillet1, Claire Laprun1, Anne Bellon1, Pedro

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD J

Fake vacancy announcements have been repeatedly circulated in the name of Debiopharm via non Debiopharm websites and email. Offers of employment or job

The company focuses on improving patients’ quality of life and has open positions.

The company offers opportunities to develop and broaden skills while contributing to patient lives.

Debiopharm Headquarters, Forum “après-demain”, Chemin Messidor 5-7, Case postale 435, 1001 Lausanne Switzerland. Tel. +41 (0)21 321 01 11, Fax. +41 (0)21 321 01 69.

Debiopharm is an independent biopharmaceutical company based in Switzerland focused on improving patient outcomes and quality of life in oncology and bacterial infections. Its activities include drug development, drug manufacturing and digital health investment.

Effective date September 10, 2018. Compliant with the Data Protection Act of Switzerland and the Regulation (EU) 2016/679 (General Data Protection

Effective as of July 1st, 2023 Debiopharm International SA, Debiopharm Research & Manufacturing SA, and Debiopharm Innovation Fund SA, which are all